FDA approves doxycycline tablets, 150 mg

Journal of Drugs in Dermatology, August, 2007 by Marissa Heller

Mylan Laboratories Inc recently announced that it has received FDA approval for doxycycline tablets, 150 mg. This medication will be the equivalent generic version of Par Pharmaceutical's doxycycline tablets, 150 mg which are currently marketed by Doak Dermatologics under the brand name Adoxa[R] Tablets. Mylan already has approval and has been marketing doxycycline tablets in 50, 75, and 10 mg strengths.

Marissa Heller MD

Department of Dermatology, Boston University School of Medicine

Pipeline Previews brings you information on the newest drugs and medical products as they become available to the dermatologic community. These features may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving FDA approval. We trust you will find this information beneficial to your practice and research.